Compound Evidence File
#EC-2026-0656
Romosozumab
Filed under Peptides. The bureau holds 146 laboratory returns for this compound from 52 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
52 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 10.0 | 10.0 | 1 Nov 2025 | 10 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Mar 2026 | 18 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 10.0 | 10.0 | 15 Apr 2026 | 10 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Mar 2026 | 7 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 10.0 | 9.9 | 10.0 | 1 Mar 2026 | 18 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Feb 2026 | 28 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 28 Dec 2025 | 16 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 3 May 2026 | 24 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 10.0 | 10.0 | 9 Jan 2026 | 15 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Dec 2025 | 26 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 13 May 2026 | 14 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 9.9 | 9.9 | 10.0 | 15 Mar 2026 | 22 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Jan 2026 | 16 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Feb 2026 | 11 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 9.9 | 5 Mar 2026 | 8 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 9.9 | 9.9 | 9.9 | 27 Mar 2026 | 16 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 2 Nov 2025 | 21 Jan 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 9.9 | 1 May 2026 | 4 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 22 May 2026 | 2 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 21 Jun 2026 | 9 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 13 Aug 2026 | 13 Aug 2026 |
| Rayshine Peptide BiochemicalsCASE #VI-2026-0545 | X | 1 | 9.3 | 9.3 | 9.3 | 2 Apr 2025 | 2 Apr 2025 |
| The Naughty NeedleCASE #VI-2026-0432 | X | 1 | 9.0 | 9.0 | 9.0 | 27 Feb 2025 | 27 Feb 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.9 | 8.8 | 9.1 | 21 May 2026 | 21 May 2026 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 2 | 8.9 | 8.4 | 9.5 | 11 Jun 2025 | 21 May 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 1 | 8.7 | 8.7 | 8.7 | 7 May 2025 | 7 May 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.5 | 7.4 | 9.1 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 8.4 | 6.9 | 9.5 | 21 May 2026 | 21 May 2026 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 2 | 8.3 | 6.8 | 9.9 | 27 Feb 2025 | 17 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 8.2 | 7.2 | 9.2 | 24 May 2026 | 24 May 2026 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 8.1 | 8.1 | 8.1 | 11 Jun 2025 | 11 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.0 | 6.0 | 9.4 | 24 May 2026 | 24 May 2026 |
| Reta-PeptideCASE #VI-2026-0756 | X | 9 | 8.0 | 4.8 | 10.0 | 13 Feb 2025 | 17 May 2026 |
| Simple PeptideCASE #VI-2026-0782 | X | 2 | 7.8 | 7.1 | 8.5 | 20 Jun 2025 | 17 May 2026 |
| Lux Synth AminosCASE #VI-2026-0700 | X | 1 | 7.8 | 7.8 | 7.8 | 2 Jul 2025 | 2 Jul 2025 |
| LSPLCASE #VI-2026-0523 | X | 3 | 7.4 | 6.6 | 8.5 | 13 Jun 2025 | 20 May 2026 |
| Amino LairCASE #VI-2026-0413 | X | 1 | 7.0 | 7.0 | 7.0 | 20 Jun 2025 | 20 Jun 2025 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 5 | 6.7 | 5.3 | 8.9 | 8 Jul 2025 | 21 May 2026 |
| Chimera PeptidesCASE #VI-2026-0260 | X | 1 | 6.4 | 6.4 | 6.4 | 16 Mar 2025 | 16 Mar 2025 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 6.4 | 6.4 | 6.4 | 17 Dec 2024 | 17 Dec 2024 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 4 | 6.3 | 5.4 | 7.4 | 21 May 2025 | 21 May 2026 |
| ZhuoYan labCASE #VI-2026-0902 | X | 1 | 5.9 | 5.9 | 5.9 | 17 Dec 2024 | 17 Dec 2024 |
| OmegAminoCASE #VI-2026-0014 | X | 1 | 5.5 | 5.5 | 5.5 | 16 Mar 2025 | 16 Mar 2025 |
| Liberty PeptidesCASE #VI-2026-0416 | X | 1 | 5.2 | 5.2 | 5.2 | 7 May 2025 | 7 May 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 2 | 4.9 | 4.6 | 5.2 | 20 Jun 2025 | 23 May 2026 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 4.7 | 4.7 | 4.7 | 6 May 2025 | 6 May 2025 |
| Amplified AminoCASE #VI-2026-0748 | X | 1 | 4.3 | 4.3 | 4.3 | 3 Jun 2025 | 3 Jun 2025 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 3.4 | 3.4 | 3.4 | 20 Jun 2025 | 20 Jun 2025 |
| Guangzhou Yuao TradingCASE #VI-2026-0787 | X | 1 | 0.8 | 0.8 | 0.8 | 24 Apr 2025 | 24 Apr 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 0.0 | 0.0 | 0.0 | 13 Jun 2025 | 13 Jun 2025 |
Open any subject to view the batch-level evidence for Romosozumab alone.